Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| BIIB | Biogen, Inc. | 1.22% | 303.04 | 1.4% | $588.11m | |
| AMGN | Amgen, Inc. | 0.21% | 233.90 | 1.3% | $519.01m | |
| GILD | Gilead Sciences, Inc. | 1.93% | 67.20 | 1.0% | $370.61m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.03% | 372.12 | 2.6% | $303.57m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.02% | 223.02 | 1.9% | $268.06m | |
| ILMN | Illumina, Inc. | 2.24% | 326.98 | 3.5% | $238.31m | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 2.90% | 67.43 | 12.0% | $192.64m | |
| EXAS | EXACT Sciences Corp. | 3.55% | 86.58 | 24.0% | $184.78m | |
| CLVS | Clovis Oncology, Inc. | 11.51% | 9.88 | 14.7% | $180.78m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 5.51% | 113.34 | 2.0% | $179.50m | |
| SRPT | Sarepta Therapeutics, Inc. | -0.29% | 109.65 | 14.6% | $148.41m | |
| A | Agilent Technologies, Inc. | 0.68% | 82.08 | 1.6% | $141.44m | |
| BMRN | BioMarin Pharmaceutical, Inc. | 0.69% | 80.63 | 4.3% | $130.99m | |
| SGEN | Seattle Genetics, Inc. | 0.43% | 117.66 | 6.1% | $128.43m | |
| NBIX | Neurocrine Biosciences, Inc. | -0.48% | 115.93 | 5.0% | $126.96m |
Company Profile
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla's investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.